Glycine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Glycine: Nasal cavity disease
One-Sentence Summary
Glycine is an amino acid product. The TxGNN model (deep learning) predicts nasal cavity disease as a possible new indication. The TxGNN model predicts it may be effective for nasal cavity disease, but there are no relevant clinical trials and no relevant publications supporting this direction. The prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9985 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. The high prediction score for nasal cavity disease comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The score may therefore reflect similarity between indication classes rather than independent evidence. The trial and literature records retrieved do not connect glycine to nasal pathology, so no mechanistic rationale can be established from the data compiled for this report.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01806675 | Phase 1/2 | Completed | 25 | PET imaging of a new radiopharmaceutical (18F-FPPRGD2) in cancer patients receiving antiangiogenesis treatment. This is a diagnostic imaging study and does not test glycine or nasal disease. |
No trial directly supports glycine for nasal cavity disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7771054 | 1995 | Basic research (animal tissue) | Veterinary Pathology | Lectin histochemistry of normal and herpesvirus-infected bovine nasal mucosa. It does not involve glycine as a treatment. |
| 29607903 | 2018 | Preclinical formulation study | Chemical & Pharmaceutical Bulletin | Oligoarginine-polymer conjugates as mucosal adjuvants for nasal vaccination in mice. It does not involve glycine as a treatment. |
Neither publication provides clinical evidence for glycine in nasal cavity disease.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10195N | Glycine500 | Sachets of oral powder, 4 g containing 500 mg glycine, 30 sachets | Not available |
Only an oral formulation is listed. Route compatibility with nasal cavity disease has not been assessed.
Safety Considerations
- Contraindications from the knowledge graph (not label text): The TxGNN knowledge graph lists contraindication links with several disease groups. These should be verified against the Product Information.
- Kidney disease (including chronic kidney disease, chronic renal failure and end-stage renal failure) and nephrolithiasis
- Calcium and phosphate disorders (hypercalcaemia, hyperparathyroidism, hyperphosphataemia, nephrocalcinosis)
- Cardiovascular conditions (heart disease, ventricular fibrillation, digitalis poisoning)
- Phenylketonuria and other disorders of phenylalanine metabolism
- Others, including sarcoidosis, hypervitaminosis, constipation disorder and lytic metastatic bone lesions
- Drug Interactions: No interaction records were found.
No label-based warnings or contraindications were available. Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high model score alone (L5). There are no relevant clinical trials or publications, mechanism data are missing, and no approved indication text or label safety data were available. The score may reflect similarity to existing upper airway indications rather than independent evidence.
To proceed, the following is needed:
- Mechanism of action data for glycine (for example from DrugBank) and a plausible mechanistic link to nasal pathology
- The approved indication text and Product Information (warnings and contraindications) for the Australian listing
- Preclinical or clinical studies of glycine in nasal cavity disease
- An assessment of whether an oral sachet is a suitable route for a nasal condition
- A review of the knowledge-graph contraindication signals, especially renal, cardiovascular and phenylketonuria-related ones
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.